JP2005510246A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005510246A5 JP2005510246A5 JP2003547635A JP2003547635A JP2005510246A5 JP 2005510246 A5 JP2005510246 A5 JP 2005510246A5 JP 2003547635 A JP2003547635 A JP 2003547635A JP 2003547635 A JP2003547635 A JP 2003547635A JP 2005510246 A5 JP2005510246 A5 JP 2005510246A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- referred
- heavy chain
- antibody
- functional fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000008186 Collagen Human genes 0.000 claims description 39
- 108010035532 Collagen Proteins 0.000 claims description 39
- 229920001436 collagen Polymers 0.000 claims description 39
- 230000027455 binding Effects 0.000 claims description 21
- 150000001413 amino acids Chemical class 0.000 claims description 20
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 9
- 238000006467 substitution reaction Methods 0.000 claims description 9
- 239000012634 fragment Substances 0.000 claims 242
- 239000008194 pharmaceutical composition Substances 0.000 claims 89
- 108090000765 processed proteins & peptides Proteins 0.000 claims 32
- 229920001184 polypeptide Polymers 0.000 claims 29
- 102000004196 processed proteins & peptides Human genes 0.000 claims 29
- 230000001225 therapeutic effect Effects 0.000 claims 10
- 230000002401 inhibitory effect Effects 0.000 claims 6
- 230000002491 angiogenic effect Effects 0.000 claims 4
- 230000008685 targeting Effects 0.000 claims 4
- 210000005166 vasculature Anatomy 0.000 claims 4
- 206010027476 Metastases Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 230000033115 angiogenesis Effects 0.000 claims 2
- 230000009401 metastasis Effects 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 230000004614 tumor growth Effects 0.000 claims 2
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims 1
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 description 6
- 230000035772 mutation Effects 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/995,529 US7365167B2 (en) | 2001-11-26 | 2001-11-26 | Humanized collagen antibodies and related methods |
| US10/011,250 US7390885B2 (en) | 2001-11-26 | 2001-12-06 | Humanized collagen antibodies and related methods |
| PCT/US2002/038147 WO2003046204A2 (en) | 2001-11-26 | 2002-11-26 | Humanized collagen antibodies and related methods |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009167279A Division JP2009240324A (ja) | 2001-11-26 | 2009-07-15 | ヒト化コラーゲン抗体および関連方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005510246A JP2005510246A (ja) | 2005-04-21 |
| JP2005510246A5 true JP2005510246A5 (enExample) | 2006-01-12 |
| JP4519464B2 JP4519464B2 (ja) | 2010-08-04 |
Family
ID=26682164
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003547635A Expired - Fee Related JP4519464B2 (ja) | 2001-11-26 | 2002-11-26 | ヒト化コラーゲン抗体および関連方法 |
| JP2009167279A Withdrawn JP2009240324A (ja) | 2001-11-26 | 2009-07-15 | ヒト化コラーゲン抗体および関連方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009167279A Withdrawn JP2009240324A (ja) | 2001-11-26 | 2009-07-15 | ヒト化コラーゲン抗体および関連方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US7390885B2 (enExample) |
| EP (1) | EP1478764B1 (enExample) |
| JP (2) | JP4519464B2 (enExample) |
| CN (1) | CN1596313B (enExample) |
| AT (1) | ATE509955T1 (enExample) |
| AU (1) | AU2009200070A1 (enExample) |
| CA (1) | CA2468016A1 (enExample) |
| IL (1) | IL162117A0 (enExample) |
| MX (1) | MXPA04004857A (enExample) |
| NZ (1) | NZ533408A (enExample) |
| WO (1) | WO2003046204A2 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7658924B2 (en) | 2001-10-11 | 2010-02-09 | Amgen Inc. | Angiopoietin-2 specific binding agents |
| US7365167B2 (en) | 2001-11-26 | 2008-04-29 | Cell Matrix, Inc. | Humanized collagen antibodies and related methods |
| US7541440B2 (en) * | 2002-09-30 | 2009-06-02 | Immunomedics, Inc. | Chimeric, human and humanized anti-granulocyte antibodies and methods of use |
| WO2005080432A2 (en) | 2004-02-19 | 2005-09-01 | Genentech, Inc. | Cdr-repaired antibodies |
| CA2619654A1 (en) * | 2005-08-24 | 2007-03-01 | Cell Matrix | Combination therapies for inhibiting integrin-extracellular matrix interactions |
| WO2007146401A2 (en) * | 2006-06-14 | 2007-12-21 | Cell-Matrix, Inc. | Denatured collagen peptides and uses thereof |
| AU2007276294B2 (en) * | 2006-06-30 | 2012-11-29 | Novo Nordisk A/S | Anti-NKG2A antibodies and uses thereof |
| EP2099826B1 (en) * | 2007-01-05 | 2013-10-16 | University Of Zurich | Anti-beta-amyloid antibody and uses thereof |
| US8048420B2 (en) | 2007-06-12 | 2011-11-01 | Ac Immune S.A. | Monoclonal antibody |
| US8613923B2 (en) | 2007-06-12 | 2013-12-24 | Ac Immune S.A. | Monoclonal antibody |
| EP2586795B1 (en) | 2007-10-05 | 2018-05-16 | Genentech, Inc. | Use of anti-amyloid beta antibody in ocular diseases |
| JO2913B1 (en) | 2008-02-20 | 2015-09-15 | امجين إنك, | Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses |
| JP5593488B2 (ja) * | 2008-11-17 | 2014-09-24 | 独立行政法人国立がん研究センター | 癌間質の構成因子に対して特異的結合能を有する物質と抗腫瘍性化合物との複合体による新規の癌ターゲティング治療 |
| EP3173792B1 (en) * | 2009-03-30 | 2019-06-12 | Nordic Bioscience A/S | Crp neo-epitope fibrosis assay |
| CA2773356A1 (en) * | 2009-10-20 | 2011-04-28 | Maine Medical Center | Compositions and methods for treating inflammation and fibrosis |
| EP2544694B1 (en) * | 2010-03-02 | 2018-10-31 | Novelmed Therapeutics, Inc. | A method for inhibiting alternative pathway mediated disorders with anti-properdin antibodies that inhibit c5 interactions with properdin |
| MY164579A (en) | 2010-07-30 | 2018-01-15 | Ac Immune Sa | Safe and functional humanized antibodies |
| JP5876833B2 (ja) | 2010-11-10 | 2016-03-02 | 日本化薬株式会社 | 抗１本鎖ｉｖ型コラーゲンポリペプチド抗体、並びに該抗体を含む医薬、及び腫瘍の診断薬、予防薬、又は治療薬 |
| BR112014006390A2 (pt) * | 2011-09-19 | 2017-03-28 | Kymab Ltd | anticorpos, domínios variáveis e cadeias feitos especialmente para uso humano |
| US9777055B2 (en) | 2012-04-20 | 2017-10-03 | Thomas Jefferson University | Engineered antibody for inhibition of fibrosis |
| CN104870474B (zh) | 2012-10-04 | 2019-03-12 | 诺沃姆德治疗公司 | 用于治疗溶血性疾病的旁路途径特异性抗体 |
| US9725520B2 (en) | 2013-03-14 | 2017-08-08 | The Board Of Regents Of The University Of Texas System | HER3 specific monoclonal antibodies for diagnostic and therapeutic use |
| ES2982558T3 (es) * | 2016-09-21 | 2024-10-16 | Nextcure Inc | Anticuerpos para Siglec-15 y métodos de uso de los mismos |
| JP7474702B2 (ja) | 2018-03-28 | 2024-04-25 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | エキソソームから単離されたｄｎａにおけるエピジェネティック変化の同定法 |
| EP3866831A4 (en) * | 2018-10-16 | 2022-08-24 | Board of Regents, The University of Texas System | IDENTIFICATION AND TARGETING OF PATHOGENIC EXTRACELLULAR MATRIX FOR DIAGNOSIS AND TREATMENT OF CANCER AND OTHER DISEASES |
| CN113330034A (zh) * | 2018-11-16 | 2021-08-31 | 阿尔伯特爱因斯坦医学院 | 针对B7-H3的IgV结构域的单克隆抗体及其用途 |
| WO2020156439A1 (zh) * | 2019-01-28 | 2020-08-06 | 上海拓界生物医药科技有限公司 | 抗cd79b抗体、其抗原结合片段及其医药用途 |
| WO2021252974A2 (en) * | 2020-06-11 | 2021-12-16 | Proviva Therapeutics (Hong Kong) Limited | Collagen-targeted fusion proteins and antibodies |
| WO2022147298A1 (en) * | 2020-12-31 | 2022-07-07 | Seattle Children's Hospital D/B/A Seattle Children's Research Institute | Vascular-endothelial cadherin activating antibodies and uses thereof |
| US20240358850A1 (en) * | 2023-04-13 | 2024-10-31 | MaineHealth | Compositions and methods for an antibody drug conjugate directed to a non-cell surface therapeutic target |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US91482A (en) * | 1869-06-15 | Improvement in harvesters | ||
| US4342566A (en) | 1980-02-22 | 1982-08-03 | Scripps Clinic & Research Foundation | Solid phase anti-C3 assay for detection of immune complexes |
| JPS6019790A (ja) | 1983-07-14 | 1985-01-31 | Yakult Honsha Co Ltd | 新規なカンプトテシン誘導体 |
| CA1264738A (en) | 1984-12-04 | 1990-01-23 | Eli Lilly And Company | Treatment of tumors in mammals |
| US5092885A (en) | 1987-02-12 | 1992-03-03 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Peptides with laminin activity |
| US5320970A (en) | 1987-11-06 | 1994-06-14 | Washington Research Foundation | Detection of collagen degradation in vivo |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US6020145A (en) | 1989-06-30 | 2000-02-01 | Bristol-Myers Squibb Company | Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96 |
| US5112946A (en) | 1989-07-06 | 1992-05-12 | Repligen Corporation | Modified pf4 compositions and methods of use |
| US5192744A (en) | 1990-01-12 | 1993-03-09 | Northwestern University | Method of inhibiting angiogenesis of tumors |
| DE69114782T2 (de) | 1990-08-08 | 1996-04-18 | Takeda Chemical Industries Ltd | Intravaskulär embolisierendes Mittel mit Gehalt an einem die Angiogenesis hemmenden Stoff. |
| US5264563A (en) | 1990-08-24 | 1993-11-23 | Ixsys Inc. | Process for synthesizing oligonucleotides with random codons |
| US5871974A (en) | 1990-09-28 | 1999-02-16 | Ixsys Inc. | Surface expression libraries of heteromeric receptors |
| JP3105629B2 (ja) | 1991-04-23 | 2000-11-06 | サングスタット メディカル コーポレイション | 特異的結合ペアのメンバーの細胞活性調節接合体 |
| DE69230545T2 (de) | 1991-08-21 | 2000-07-06 | Novartis Ag, Basel | Antikörperderivate |
| DE4127790A1 (de) | 1991-08-22 | 1993-02-25 | Wank Anna | Verwendung von oligopeptiden mit 2 bis 5 peptidbindungen fuer kosmetische zwecke und einige neue oligopeptid-metallkomplexe |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| JPH0675216A (ja) | 1992-08-27 | 1994-03-18 | Hitachi Ltd | 液晶表示装置 |
| US6132976A (en) | 1992-12-04 | 2000-10-17 | Shriners Hospitals For Children | Immunoassays for the measurement of collagen denaturation and cleavage in cartilage |
| CA2148132A1 (en) | 1992-12-04 | 1994-06-23 | Anthony Robin Poole | Immunoassay for the measurement of collagen cleavage in cartilage |
| US5541295A (en) | 1993-02-12 | 1996-07-30 | The Board Of Governors For Higher Education State Of Rhode Island And Providence Plantations | Detection of type II collagen and its peptides |
| DK0711415T3 (da) | 1993-07-28 | 1999-04-26 | Roche Diagnostics Gmbh | Immunoanalyse til påvisning af collagen eller collagenfragmenter |
| US5510391A (en) | 1993-10-22 | 1996-04-23 | Mayapple Holdings, Llc | Method of treating blood vessel disorders of the skin using vitamin K |
| US5465826A (en) | 1994-02-24 | 1995-11-14 | Valiant Machine & Tool, Inc. | Conveyor system |
| US5560910A (en) | 1994-08-26 | 1996-10-01 | Crandall; Wilson T. | Topical anti-inflammatory composition and method |
| US5783184A (en) | 1994-12-23 | 1998-07-21 | Smithkline Beecham Corporation | Method for treatment and diagnosis of IL-5 mediated disorders |
| US5763272A (en) | 1994-12-23 | 1998-06-09 | Boehringer Mannheim Gmbh | Hybridoma for producing antibody for collagen I |
| US5756775A (en) | 1995-12-13 | 1998-05-26 | Eli Lilly And Company | Process to make α,α-difluoro-β-hydroxyl thiol esters |
| US6001994A (en) | 1995-12-13 | 1999-12-14 | Eli Lilly And Company | Process for making gemcitabine hydrochloride |
| AU2804297A (en) | 1996-04-22 | 1997-11-12 | Advanced Polymer Systems Inc. | Method of and composition for treating disorders of the skin using vitamin k |
| WO1997044059A2 (en) | 1996-05-23 | 1997-11-27 | Shriner's Hospitals For Children | Cartilage type ii collagen as an angiogenic factor |
| US6492508B1 (en) | 1996-06-03 | 2002-12-10 | United States Surgical Corp. A Division Of Tyco Healthcare Group | Nucleic acids encoding extracellular matrix proteins |
| WO1999011208A1 (en) | 1997-08-28 | 1999-03-11 | Williams C Donald | Method and composition for transdermal administration of pharmacologic agents |
| US6590079B2 (en) * | 1997-01-30 | 2003-07-08 | Ixsys, Incorporated | Anti-αvβ3 recombinant human antibodies, nucleic acids encoding same |
| GB9702252D0 (en) | 1997-02-06 | 1997-03-26 | Univ Sheffield Medical The Sch | Collagen assay |
| US5817699A (en) | 1997-05-30 | 1998-10-06 | Flores; John A. | Process for the preparation of ketamine ointment |
| WO1999006840A1 (en) | 1997-07-31 | 1999-02-11 | Metra Biosystems, Inc. | Collagen-peptide assay method |
| AU8691398A (en) | 1997-08-04 | 1999-02-22 | Ixsys, Incorporated | Methods for identifying ligand specific binding molecules |
| US6030792A (en) | 1997-11-13 | 2000-02-29 | Pfizer Inc | Assays for measurement of protein fragments in biological media |
| BR9915543A (pt) | 1998-10-16 | 2001-08-14 | Fraunhofer Ges Forschung | Resistência a doenças por plantas mediada por patogenicidas moleculares |
| US6833373B1 (en) * | 1998-12-23 | 2004-12-21 | G.D. Searle & Co. | Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia |
| CA2358517C (en) | 1999-01-06 | 2012-10-09 | University Of Southern California | Method and composition for angiogenesis inhibition |
| US6521593B1 (en) | 1999-02-01 | 2003-02-18 | Childrens Hospital Los Angeles | Methods for inhibiting brain tumor growth |
| US6531580B1 (en) | 1999-06-24 | 2003-03-11 | Ixsys, Inc. | Anti-αvβ3 recombinant human antibodies and nucleic acids encoding same |
| CA2379373A1 (en) | 1999-07-13 | 2001-01-18 | University Of Southern California | Novel method and composition for inhibition of angiogenesis using antagonists based on mmp-9 and .beta.1 integrins |
| CA2385614A1 (en) | 1999-10-13 | 2001-04-19 | Timothy Johann | Multiplex cytokine analysis |
| US6849425B1 (en) | 1999-10-14 | 2005-02-01 | Ixsys, Inc. | Methods of optimizing antibody variable region binding affinity |
| MXPA02007449A (es) | 2000-02-03 | 2003-04-14 | Millennium Pharm Inc | Anticuerpos anti-ccr2 humanizados y metodos para el uso de los mismos. |
| WO2001066144A2 (en) | 2000-03-08 | 2001-09-13 | Rhode Island Hospital, A Lifespan Partner | Antineoplastic combination comprising an inhibitor of angiogenesis and an inhibitor of dna topoisomerase i enzyme activity |
| US6696254B2 (en) | 2001-11-21 | 2004-02-24 | Kimberly-Clark Worldwide, Inc. | Detection and identification of enteric bacteria |
| US7365167B2 (en) | 2001-11-26 | 2008-04-29 | Cell Matrix, Inc. | Humanized collagen antibodies and related methods |
| US20040241776A1 (en) | 2003-05-22 | 2004-12-02 | Agdia, Inc. | Multiplex enzyme-linked immunosorbent assay for detecting multiple analytes |
| JP2005347062A (ja) | 2004-06-02 | 2005-12-15 | Hitachi Displays Ltd | バックライト装置及び液晶表示装置 |
| JP2006075216A (ja) | 2004-09-07 | 2006-03-23 | Toshiba Corp | 医用画像処理システム、医用画像処理プログラムおよび医用画像処理方法 |
| WO2007146401A2 (en) | 2006-06-14 | 2007-12-21 | Cell-Matrix, Inc. | Denatured collagen peptides and uses thereof |
-
2001
- 2001-12-06 US US10/011,250 patent/US7390885B2/en not_active Expired - Fee Related
-
2002
- 2002-11-26 IL IL16211702A patent/IL162117A0/xx unknown
- 2002-11-26 JP JP2003547635A patent/JP4519464B2/ja not_active Expired - Fee Related
- 2002-11-26 EP EP02795695A patent/EP1478764B1/en not_active Expired - Lifetime
- 2002-11-26 CA CA002468016A patent/CA2468016A1/en not_active Abandoned
- 2002-11-26 AT AT02795695T patent/ATE509955T1/de not_active IP Right Cessation
- 2002-11-26 MX MXPA04004857A patent/MXPA04004857A/es not_active Application Discontinuation
- 2002-11-26 NZ NZ533408A patent/NZ533408A/en not_active IP Right Cessation
- 2002-11-26 CN CN028264126A patent/CN1596313B/zh not_active Expired - Fee Related
- 2002-11-26 WO PCT/US2002/038147 patent/WO2003046204A2/en not_active Ceased
-
2006
- 2006-07-14 US US11/486,894 patent/US7566770B2/en not_active Expired - Fee Related
-
2008
- 2008-05-08 US US12/117,642 patent/US7763248B2/en not_active Expired - Fee Related
-
2009
- 2009-01-08 AU AU2009200070A patent/AU2009200070A1/en not_active Abandoned
- 2009-07-15 JP JP2009167279A patent/JP2009240324A/ja not_active Withdrawn
-
2010
- 2010-06-10 US US12/813,352 patent/US20100303726A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005510246A5 (enExample) | ||
| JP2024167313A5 (enExample) | ||
| JP2025111463A5 (enExample) | ||
| JP2025160458A5 (enExample) | ||
| JP2022031635A5 (enExample) | ||
| JP2011509245A5 (enExample) | ||
| HRP20181069T1 (hr) | Antagonistička protutijela na il-17 | |
| ME02581B (me) | Farmaceutski pripravci s otpornošću na topljivi cea | |
| JP2009225799A5 (enExample) | ||
| JP2005519580A5 (enExample) | ||
| JP2005503789A5 (enExample) | ||
| JP2004527212A5 (enExample) | ||
| JP2010502183A5 (enExample) | ||
| JP2020531438A5 (ja) | Ｎｋｇ２ｄ、ｃｄ１６、およびｈｌａ−ｅに結合するタンパク質 | |
| JP2010533498A5 (enExample) | ||
| JP2010536384A5 (enExample) | ||
| JP2008532949A5 (enExample) | ||
| JP2010511388A5 (enExample) | ||
| WO2002072832A3 (en) | Therapeutic binding molecules | |
| JP2008538292A5 (enExample) | ||
| JP2012500020A5 (enExample) | ||
| JP2018537421A5 (enExample) | ||
| JP2010524435A5 (enExample) | ||
| JP2012532851A5 (enExample) | ||
| WO2005026210A3 (en) | Therapeutic binding molecules |